Effects of Atorvastatin on Number and Function of Pro-inflammatory CD4+CD28null T-cells and Defective Treg in Patients with Acute Coronary Syndromes.

Trial Profile

Effects of Atorvastatin on Number and Function of Pro-inflammatory CD4+CD28null T-cells and Defective Treg in Patients with Acute Coronary Syndromes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Atorvastatin (Primary) ; Pravastatin
  • Indications Acute coronary syndromes
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Oct 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 05 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top